PI3K/AKT/mTOR pathway blockade with pan-PI3K/mTORC1/2 inhibition produced substantial PFS gains in PIK3CA wild-type disease, addressing an unmet need after CDK4/6 plus endocrine resistance. Adding ...

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) ...

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.

Barclays 28th Annual Global Healthcare Conference March 11, 2026 10:30 AM EDTCompany ParticipantsSanjiv Patel - ...

CEO and co-founder Brian Sullivan outlined the company’s clinical programs, regulatory progress, and commercial launch preparations for gedatolisib during a fireside chat at TD Cowen’s 46th Annual ...

Leerink Global Healthcare Conference 2026 March 10, 2026 2:20 PM EDTCompany ParticipantsBrian Sullivan - Co-Founder, Chairman ...

The study did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a ...

In ‘Evaluating Transthyretin Stabilizers and Silencers in ATTR-CM,’ our panel delves into the segment by asking Dr. Alexander to explain the differences between transthyretin ...

BACKGROUND: Aortic valve calcification increases leaflet stiffness and contributes to the development of calcific aortic valve disease. The molecular and cellular mechanisms underlying calcification ...

Community programs like Go for Bold improve health, but lasting, equitable gains require complementary structural food policies—including taxes, reformulation, and labeling—to shift environments and ...

By Tarun Sai Lomte Scientists reveal how evolution within our own tissues can drive disease, protect cells, and uncover hidden therapeutic targets for future precision medicine. Somatic genomics ...

ERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus palbocicl ...